➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,887,459

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,887,459 protect, and when does it expire?

Patent 6,887,459 protects FORADIL and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 6,887,459
Title: Aerosol composition comprising formoterol
Abstract:The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 .mu.g to 5000 .mu.g per .mu.g of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.
Inventor(s): Haeberlin; Barbara (Muenchenstein, CH)
Assignee: Novartis, AG (Basel, CH)
Application Number:10/148,043
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,887,459

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis FORADIL formoterol fumarate POWDER;INHALATION 020831-001 Feb 16, 2001 DISCN Yes No   Start Trial   Start Trial TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,887,459

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928311Nov 30, 1999
PCT Information
PCT FiledNovember 28, 2000PCT Application Number:PCT/EP00/11894
PCT Publication Date:June 07, 2001PCT Publication Number: WO01/39745

International Family Members for US Patent 6,887,459

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2837401   Start Trial
Australia 769765   Start Trial
Brazil 0015908   Start Trial
Canada 2389349   Start Trial
China 1399540   Start Trial
Czech Republic 20021850   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.